BioSniper
Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy

June 1, 2026
Company
Arcus Biosciences, Inc. (RCUS)
Drug
domvanalimab
Indication
Advanced Upper Gastrointestinal Tract Adenocarcinoma

Other upcoming events for RCUS

Phase 2 StartPhase 2 Start: PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOS
Jul 1, 2026
Phase 1 StartPhase 1 Start: A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascendin
Jul 1, 2026
Phase 3 ReadoutPhase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chem
Nov 30, 2030
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib
Dec 1, 2030
Patent ExpiryPatent/Exclusivity Expiry: PEMETREXED
Mar 26, 2035

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
RCUS OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About
  • Data Methodology

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle